- Home
- NAGE vs LAB Comparison
NAGE vs LAB Comparison
Compare NAGE & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | LAB |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.6M | 488.4M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | NAGE | LAB |
|---|---|---|
| Price | $6.57 | $1.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $16.33 | $1.35 |
| AVG Volume (30 Days) | 807.8K | ★ 1.5M |
| Earning Date | 11-04-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1093.81 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | $124,709,000.00 | ★ $169,737,000.00 |
| Revenue This Year | $30.37 | N/A |
| Revenue Next Year | $20.36 | N/A |
| P/E Ratio | $28.78 | ★ N/A |
| Revenue Growth | 36.04 | ★ 79.77 |
| 52 Week Low | $5.16 | $0.92 |
| 52 Week High | $14.69 | $2.14 |
Technical Indicators
Market Signals| Indicator | NAGE | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 41.08 |
| Support Level | $6.18 | $1.24 |
| Resistance Level | $6.86 | $1.34 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 49.14 | 10.20 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.